Online:
Visits:
Stories:
Profile image
By marketresearchnest
Contributor profile | More stories
Story Views

Now:
Last Hour:
Last 24 Hours:
Total:

Allergic Conjunctivitis Therapeutics Market Pipeline Review H1 2017

Thursday, May 18, 2017 5:17
% of readers think this story is Fact. Add your two cents.

(Before It's News)

MarketResearchNest.com adds “Allergic Conjunctivitis – Pipeline Review, H1 2017” new report to its research database. The report spread across in multiple pages with table and figures in it.

 

Latest Pharmaceutical and Healthcare disease pipeline guide Allergic Conjunctivitis – Pipeline Review, H1 2017, provides an overview of the Allergic Conjunctivitis (Ophthalmology) pipeline landscape.

Allergic conjunctivitis occurs when the clear layer of tissue lining the eyelids and covering the white of the eye (conjunctiva) become swollen or inflamed due to a reaction to pollen, dander, mold, or other allergy-causing substances. Symptoms include intense itching, puffy eyelids, widened (dilated) vessels in the clear tissue covering the white of the eye and stringy eye discharge. Treatment includes antihistamine or anti-inflammatory medication.

Browse full table of contents and data tables at https://www.marketresearchnest.com/allergic-conjunctivitis-pipeline-review-h1-2017.html

The Allergic Conjunctivitis (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Allergic Conjunctivitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 2, 3, 2, 10 and 1 respectively.

Allergic Conjunctivitis (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

 

Allergic Conjunctivitis – Companies Involved in Therapeutics Development

Accolade Pharmaceuticals LLC

Aldeyra Therapeutics Inc

AlleCures Inc

Allergan Plc

Clevexel Pharma SAS

Griffin Discoveries BV

NicOx SA

Ocular Therapeutix Inc

Ohr Pharmaceutical Inc

Portola Pharmaceuticals Inc

Re-Pharm Ltd

Realm Therapeutics Plc

Sylentis SAU

Xencor Inc

 

Order a Purchase Report Copy at https://www.marketresearchnest.com/purchase.php?reportid=205667

 

Featured News & Press Releases
Apr 18, 2017: Aldeyra Therapeutics Announces Last Patient Dosed in Allergic Conjunctivitis Phase 2b Clinical Trial
Apr 11, 2017: Nicox announces PDUFA date for ZERVIATE NDA
Mar 09, 2017: Nicox resubmits AC-170 (ZERVIATE) NDA to the US FDA
Feb 07, 2017: Aldeyra Therapeutics Announces First Patient Enrolled in Allergic Conjunctivitis Phase 2b Clinical Trial
Jan 05, 2017: Realm Therapeutics to provide update on PR013 at the 2017 Dermatology Summit and Biotech Showcase
Dec 05, 2016: Noveome Initiates Phase 2 Clinical Trial of ST266 for the Treatment of Allergic Conjunctivitis
Nov 16, 2016: PuriCore provides update on key development program PR013
Nov 09, 2016: Nicox Provides Update on Latanoprostene bunod and AC-170
Nov 07, 2016: Aldeyra Therapeutics Announces Presentation of Phase 2 Allergic Conjunctivitis Results at the 2016 American College of Allergy, Asthma and Immunology Annual Scientific Meeting
Oct 10, 2016: Nicox Receives Complete Response Letter from the FDA Related to GMP on NDA for AC-170
Sep 26, 2016: Aldeyra Therapeutics Provides Update on Late-Stage Clinical Trials at 2016 Research and Development Day
Jun 21, 2016: U.S. FDA grants Priority Review for Nicox AC-170 New Drug Application
Jun 06, 2016: Ocular Therapeutix Announces Topline Results of Second Phase 3 Clinical Trial of DEXTENZA for the Treatment of Allergic Conjunctivitis
Apr 19, 2016: Nicox submits New Drug Application for AC-170 to U.S. FDA
Feb 29, 2016: Aldeyra Therapeutics Reports Positive Results From Phase IIa Clinical Trial in Subjects With Allergic Conjunctivitis

 

Scope of this Report

- The pipeline guide provides a snapshot of the global therapeutic landscape of Allergic Conjunctivitis (Ophthalmology).
- The pipeline guide reviews pipeline therapeutics for Allergic Conjunctivitis (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Allergic Conjunctivitis (Ophthalmology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Allergic Conjunctivitis (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Allergic Conjunctivitis (Ophthalmology)

 

Request Sample Copy at https://www.marketresearchnest.com/requestsample.php?reportid=205667

 

About Us:                         

MarketResearchNest.com is the most comprehensive collection of market research products and services on the Web. We offer reports from almost all top publishers and update our collection on daily basis to provide you with instant online access to the world’s most complete and recent database of expert insights on global industries, organizations, products, and trends.

 

Contact Us

Mr. Jeet Jain

Sales Manager

[email protected]

+1-240-284-8070

Connect with us:  Google+ | LinkedIn | Twitter | Facebook

Report abuse

Comments

Your Comments
Question   Razz  Sad   Evil  Exclaim  Smile  Redface  Biggrin  Surprised  Eek   Confused   Cool  LOL   Mad   Twisted  Rolleyes   Wink  Idea  Arrow  Neutral  Cry   Mr. Green

Top Stories
Recent Stories
 

Featured

 

Top Global

 

Top Alternative

 

Register

Newsletter

Email this story
Email this story

If you really want to ban this commenter, please write down the reason:

If you really want to disable all recommended stories, click on OK button. After that, you will be redirect to your options page.